The Resurgence of ‘Bad Blood’: How a New Documentary Has Reignited Interest in the Theranos Saga

The Silicon Valley archetype—the visionary dropout, the black turtleneck, the promise of a world-changing technology—has long been a cornerstone of modern American mythology. Yet, no story has dismantled that archetype with as much precision and chilling detail as the collapse of Theranos. John Carreyrou’s 2018 seminal bestseller, Bad Blood: Secrets and Lies in a Silicon Valley Startup, which served as the definitive autopsy of Elizabeth Holmes’ fraudulent empire, is currently experiencing a massive resurgence in public interest.

Driven by the mid-October release of the surprise box-office phenomenon You Can See Everything, a documentary helmed by Nathan Fielder and Lance Oppenheim, the reading public has once again turned to Carreyrou’s reporting to understand the anatomy of a $9 billion lie.

Main Facts: The Anatomy of a Corporate Catastrophe

The narrative of Theranos remains one of the most significant cautionary tales in the history of the tech industry. Elizabeth Holmes, once dubbed the "next Steve Jobs," founded Theranos in 2003 with the promise of revolutionizing diagnostic medicine. Her company claimed to have developed a proprietary technology—the Edison machine—capable of performing a wide array of laboratory tests from a single, tiny drop of blood.

The promise was irresistible: affordable, accessible healthcare that would democratize diagnostics. At its zenith, the company commanded a valuation of $9 billion, with Holmes securing backing from high-profile investors and a board of directors comprised of political heavyweights. However, as investigative reporting by John Carreyrou for the Wall Street Journal eventually exposed, the technology was a mirage. The machine did not work, and the company was systematically misleading investors, regulators, and patients.

The release of You Can See Everything on October 16 has thrust this narrative back into the national consciousness. By offering a raw, fly-on-the-wall perspective of Holmes in the weeks leading up to her imprisonment in May 2023, the documentary has transformed a historical scandal into a contemporary debate, driving a sharp uptick in interest for the literary source material that first broke the story open.

Chronology: From Silicon Valley Darling to Federal Inmate

To understand the enduring relevance of Bad Blood, one must track the trajectory of the Theranos saga through the lens of time:

• 2003: Elizabeth Holmes drops out of Stanford University at age 19 to found Theranos.
• 2013–2014: Theranos enters a high-profile partnership with Walgreens, placing wellness centers in pharmacies. The company’s valuation reaches $9 billion.
• October 2015: John Carreyrou publishes his groundbreaking investigation in the Wall Street Journal, questioning the efficacy of Theranos’ technology and exposing internal whistleblowers’ concerns.
• 2018: Theranos officially dissolves. John Carreyrou publishes Bad Blood, which spends over 100 weeks on the New York Times bestseller list.
• January 2022: A federal jury convicts Holmes on four counts of wire fraud and conspiracy.
• May 2023: Holmes surrenders to federal prison to begin an 11-year sentence.
• October 2026: The documentary You Can See Everything premieres, leading to a massive spike in sales for the paperback edition of Bad Blood.

Supporting Data: The "Documentary Effect" on Literature

The impact of the documentary You Can See Everything on book sales provides a fascinating case study in how visual media consumption translates into long-form reading habits. According to data provided by Circana BookScan, which tracks the pulse of the print industry, the correlation between the documentary’s release and the resurgence of Bad Blood is undeniable.

For the week ending October 17, 2026—mere days after the film’s release—the paperback edition of Bad Blood saw sales soar to 985 copies. This represents a significant jump from the previous week, during which the book moved 439 copies. The growth is not merely a momentary fluctuation; year-to-date sales for the book are currently tracking 55% higher than during the same period in 2025.

The documentary itself has defied industry expectations, grossing $45 million over its first two weekends. This financial success signals that, despite the years that have passed since the company’s collapse, the public’s appetite for the "Theranos mystery" remains insatiable. Readers are not just looking for a summary of the facts; they are seeking the exhaustive, deep-dive reporting that only Carreyrou’s narrative non-fiction provides.

Official Responses and Legal Standing

Throughout the development of the Theranos scandal, Elizabeth Holmes has remained a polarizing figure. Following her 2022 conviction, she was sentenced to 11.25 years in federal prison. Despite the overwhelming evidence presented during the trial—including testimony regarding the falsification of lab results and the deceptive use of third-party machines to mimic Theranos’ technology—Holmes has consistently maintained her innocence.

The legal proceedings were marked by a high-stakes defense that attempted to shift blame onto former COO Ramesh "Sunny" Balwani and the culture of Silicon Valley itself. However, the prosecution successfully demonstrated a pattern of intentional deception. As of late 2026, her appeals process has largely exhausted the standard avenues, leaving her to serve her term at the federal prison camp in Bryan, Texas.

The documentary, which offers a rare, intimate look at her final days of freedom, has been met with mixed responses. While some critics praise Fielder and Oppenheim for their observational approach, others have questioned whether the film inadvertently humanizes a figure who caused significant harm to patients and investors alike. The film does not attempt to exonerate her, but its existence has undoubtedly provided a platform for renewed scrutiny of her claims.

Implications: The Enduring Legacy of ‘Bad Blood’

The resurgence of Bad Blood highlights a broader cultural shift in how we process corporate fraud. In the early 2010s, Silicon Valley was viewed through a lens of unbridled optimism. Theranos was the dark side of that optimism—a warning that "fake it until you make it" has a breaking point when applied to life-and-death medical technology.

The Role of Investigative Journalism

John Carreyrou’s work is now widely considered the gold standard for investigative journalism in the tech sector. The book’s continued relevance—nearly a decade after its initial publication—proves that audiences crave accountability. As long as the startup world continues to prioritize growth and valuation over ethics and safety, Bad Blood will remain a necessary text.

The Power of Visual Storytelling

The success of You Can See Everything serves as a reminder that visual media and literature are not competitors, but symbiotic partners. A well-produced documentary can act as a gateway, guiding a new generation of readers toward rigorous, long-form journalism. For many, the film provides the emotional hook, while the book provides the intellectual foundation.

The Future of the "Founder Cult"

Perhaps the most significant implication of this sustained interest is the shift in public perception regarding the "visionary founder." The fascination with Holmes is no longer about the potential for success, but the mechanics of failure. Investors, regulators, and the general public have become more cynical and, perhaps, more diligent. The Theranos saga has fundamentally changed the due diligence process for health-tech investments, ensuring that the "secrets and lies" documented by Carreyrou are harder to replicate in the future.

As the industry moves forward, the Theranos case will remain the benchmark for what happens when a narrative of innovation outpaces the reality of execution. And as long as people continue to be captivated by the story, John Carreyrou’s Bad Blood will remain on the shelves, serving as a reminder that in the world of technology, the most dangerous lies are the ones that sound the most like the truth.